Vyant, OrganoTherapeutics to Collaborate on Therapeutics to Treat Parkinson’s

 Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders and OrganoTherapeutics, a developer of proprietary patient-specific organoids that recapitulate Parkinson’s Disease (PD) pathology, announced today they have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson’s Disease.

The collaboration brings together the respective teams’ expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential PD drugs. Together, they will focus on the identification of drug candidates that rescue the PD phenotype through the development of disease-linked, clinically- translatable assays and biomarkers through multiple molecular, biochemical, and cellular methods. This approach will integrate and leverage OrganoTherapeutic’s complex, patient-derived, 3D-organoid disease models derived from induced pluripotent stem cells (iPSCs), and Vyant Bio’s iPSC expertise and its AnalytiXTM machine learning technology.

OrganoTherapeutics has developed Parkinson’s Disease-specific midbrain organoids from multiple PD patients, providing the ability to more fully understand drug response based on genetic differences. Robert Fremeau, PhD, Vyant Bio’s Chief Scientific Officer, states “This collaboration with OrganoTherapeutics is another example of Vyant Bio’s commitment to accelerate the discovery and development of transformative therapies for patients living with severe CNS diseases. We are pleased to announce this collaboration with OrganoTherapeutics as they bring deep knowledge and innovative approaches to Parkinson’s Disease-based drug discovery. Together, we will expand our human-first platform in neurodevelopmental disorders such as Rett Syndrome and CDKL5 deficiency disorder into Parkinson’s Disease and ultimately other neurodegenerative disorders.”

https://finance.yahoo.com/news/vyant-bio-organotherapeutics-announce-strategic-210000301.html